Investment analysts at Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $67.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 46.26% from the stock’s previous close.
A number of other equities research analysts have also weighed in on RARE. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Robert W. Baird reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Morgan Stanley reissued an “equal weight” rating and set a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, October 6th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $72.06.
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down $1.99 during trading hours on Wednesday, hitting $45.81. 362,000 shares of the stock traded hands, compared to its average volume of 404,910. The firm has a market cap of $2,030.00, a PE ratio of -6.57 and a beta of 1.83. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.
Several institutional investors have recently added to or reduced their stakes in RARE. Capital International Investors lifted its position in shares of Ultragenyx Pharmaceutical by 21.9% during the 3rd quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock valued at $154,213,000 after acquiring an additional 520,496 shares during the period. BlackRock Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 10.4% during the 2nd quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock valued at $217,237,000 after acquiring an additional 330,911 shares during the period. State Street Corp lifted its position in shares of Ultragenyx Pharmaceutical by 21.4% during the 2nd quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after acquiring an additional 270,729 shares during the period. Royal Bank of Canada lifted its position in shares of Ultragenyx Pharmaceutical by 933.2% during the 2nd quarter. Royal Bank of Canada now owns 224,261 shares of the biopharmaceutical company’s stock valued at $13,929,000 after acquiring an additional 202,556 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in shares of Ultragenyx Pharmaceutical by 27.4% during the 3rd quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock valued at $39,967,000 after acquiring an additional 161,196 shares during the period. Institutional investors own 94.10% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
